TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19954550

Group type: EXPERIMENTAL
Intervention: Preventative care program delivered at home over the first 12 months of life
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical follow‐up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventative care program
Number of subjects: 0
Study: 18085139

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX‐UE 10), once each week, 3 consecutive sessions for one course
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX‐UE 10), once every two weeks, 3 consecutive sessions for one course
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral administration of Lactein tablets, 1-2 tablets, 3 times daily for 4 weeks
Number of subjects: 42
Study: 15467633

Group type: EXPERIMENTAL
Intervention: Small-sized antrostomy (less than 6 mm)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Large-sized antrostomy (more than 16 mm)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Persistent accessory maxillary ostia, scarring within the ethmoid
Number of subjects: 133
Study: 11758180

Group type: EXPERIMENTAL
Intervention: Group A (n = 50): instructed to lay on the same lateral posture with the fetal spine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group B (n = 50): lay on the opposite side to the fetal spine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group A (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group B (n = 50)
Number of subjects: 100
Study: 9165134

Group type: COMPARATOR
Intervention: Standard fraction RT (70 Gy)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: RT plus 6 mg/m2 of cisplatin (CDPP)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: RT plus 25 mg/m2 of carboplatin (CBDCA)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: RT plus either cisplatin or carboplatin
Number of subjects: 159

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: RT plus cisplatin or carboplatin
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 159
Study: 7962385

Group type: EXPERIMENTAL
Intervention: Assisted procreation methods (IUI, GIFT, IVF)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Ovulation induction alone and IPI
Number of subjects: 346

Group type: COMPARATOR
Intervention: Spontaneous natural conception
Number of subjects: 346
Study: 2888159

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31300241

Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: MEOPA
Number of subjects: 60
Study: 29357188

Group type: EXPERIMENTAL
Intervention: Screener for Substance and Behavioural Addictions (SSBA)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Individual-behaviour screening instruments
Number of subjects: 6000
Study: 27499458

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 7009

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7009
Study: 24335056

Group type: EXPERIMENTAL
Intervention: A allele of CRY2 rs11605924
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: G allele of MTNR1B rs10830963
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Gene-diet fat interactions for CRY2
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Gene-diet fat interactions for MTNR1B
Number of subjects: 1443
Study: 24334573

Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: simvastatin/ezetimibe (10/10 mg per day)
Number of subjects: 36
Study: 20826578

Group type: EXPERIMENTAL
Intervention: Direct RIA assay
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: LC/MS at Mayo
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: LC/MS at Quest
Number of subjects: 596

Group type: COMPARATOR
Intervention: RIA
Number of subjects: 596
Study: 18812767

Group type: EXPERIMENTAL
Intervention: Lyophilized corneas
Number of subjects: 20

Group type: COMPARATOR
Intervention: Optisol corneas
Number of subjects: 20
Study: 16671429

Group type: EXPERIMENTAL
Intervention: Surgical treatment (S group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conservative treatment (C group)
Number of subjects: 16
Study: 12816783

Group type: EXPERIMENTAL
Intervention: Selenium-iodine supplementation
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Placebo-iodine supplementation
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (unsupplemented)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Iodine supplementation
Number of subjects: 324
Study: 10613996

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study: 9263147

Group type: EXPERIMENTAL
Intervention: Low load resistance exercise training program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 8230497

Group type: EXPERIMENTAL
Intervention: Potassium citrate (30 to 60 mEq daily for 3 years)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 57
Study: 3764522

Group type: EXPERIMENTAL
Intervention: Single-dose parenteral therapy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Triple-dose parenteral therapy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Parenteral and lavage therapy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Lavage therapy alone
Number of subjects: 212

Group type: COMPARATOR
Intervention: Mezlocillin (historical controls)
Number of subjects: 212
Study: 31498169

Group type: EXPERIMENTAL
Intervention: Asian residents
Number of subjects: 505

Group type: COMPARATOR
Intervention: Non-Asian residents
Number of subjects: 505
Study: 28494067

Group type: EXPERIMENTAL
Intervention: High dietary vitamin K1 intake (highest tertile)
Number of subjects: 5860

Group type: COMPARATOR
Intervention: Lowest dietary vitamin K1 intake (lowest tertile)
Number of subjects: 5860
Study: 25827255

Group type: EXPERIMENTAL
Intervention: PTH 1-84
Number of subjects: 46

Group type: COMPARATOR
Intervention: Calcium and colecalcipherol
Number of subjects: 46
Study: 23307678

Group type: EXPERIMENTAL
Intervention: Total disc replacement (TDR)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation (MDR)
Number of subjects: 173
Study: 21922974

Group type: EXPERIMENTAL
Intervention: Balloon dilation of the frontal recess
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional functional endoscopic sinus surgery (Draf I procedure)
Number of subjects: 40
Study: 18948425

Group type: EXPERIMENTAL
Intervention: Oral itraconazole (200 mg twice daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 17094745

Group type: EXPERIMENTAL
Intervention: Standard laparoscopic (SL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hand‐assisted laparoscopic (HAL)
Number of subjects: 40
Study: 14988448

Group type: EXPERIMENTAL
Intervention: Dairy protein diet (DP, 2400 mg Ca/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mixed protein sources diet (MP, 500 mg Ca/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both diets during energy restriction
Number of subjects: 50
Study: 11412288

Group type: EXPERIMENTAL
Intervention: PEEP
Number of subjects: 40

Group type: COMPARATOR
Intervention: ZEEP
Number of subjects: 40
Study: 9669391

Group type: EXPERIMENTAL
Intervention: 99mTc‐albumin colloid (AC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 99mTc‐human serum albumin (HSA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 99mTc‐sulfur colloid (SC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All agents
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Delayed imaging or localization alone
Number of subjects: 51
Study: 8054835

Group type: EXPERIMENTAL
Intervention: Mild cooling of the contralateral hand in water at 16 degrees C for 2 min, repeated six times at randomized time intervals.
Number of subjects: 20
Study: 3041558

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 152

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 152
Study: 1391671

Group type: EXPERIMENTAL
Intervention: Triazolam 0.125 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 332099

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31492652

Group type: EXPERIMENTAL
Intervention: Ozanimod 1.0 mg
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.5 mg
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 1320
Study: 27418639

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) treatment
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 224
Study: 25552364

Group type: EXPERIMENTAL
Intervention: CEF (dose-intense cyclophosphamide, epirubicin, and flurouracil)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: EC/T (dose-dense, dose-intense epirubicin, cyclophosphamide, and paclitaxel)
Number of subjects: 2104

Group type: COMPARATOR
Intervention: AC/T (doxorubicin, cyclophosphamide, and paclitaxel)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Higher continuous ROR
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Intrinsic subtypes (compared with luminal A)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Non-luminal tumors
Number of subjects: 2104
Study: 23557429

Group type: EXPERIMENTAL
Intervention: Bipolar I
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bipolar II
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 21610239

Group type: EXPERIMENTAL
Intervention: Oral prednisone (60 mg/d for 14 days with a 5-day taper)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Intratympanic methylprednisolone (4 doses over 14 days of 40 mg/mL injected into the middle ear)
Number of subjects: 250
Study: 19904567

Group type: EXPERIMENTAL
Intervention: PSE-enriched margarine (2.5 g/day of plant stanols)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 28
Study: 16739847

Group type: EXPERIMENTAL
Intervention: Blood-letting therapy combined with tapping Huatuo Jiaji (EX-B2) on the back by plum-blossom needle, once daily for 6 times (1 course)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine acupuncture at points of the four limbs, once daily for 12 times (1 course)
Number of subjects: 95
Study: 15534521

Group type: EXPERIMENTAL
Intervention: Minimally invasive total knee replacement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard technique)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 11673746

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 9612237

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate (phi B) at a dose of 0.36 g.kg‐1.day‐1 for 24 hours
Number of subjects: 9
Study: 7742261

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 209

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 209
Study: 31192682

Group type: EXPERIMENTAL
Intervention: PUFA Ω‐3 (2.4 g/day; EPA 1.6 g and DHA 0.8 g)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 28454533

Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTOs)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Any exposure to CTO
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: CTO exposure
Number of subjects: 333

Group type: COMPARATOR
Intervention: CTOs
Number of subjects: 333
Study: 26304969

Group type: EXPERIMENTAL
Intervention: 3-month diabetes self-management education (DSME) program followed by 12 months of weekly group sessions and supplementary telephone support delivered by peer leaders
Number of subjects: 106

Group type: COMPARATOR
Intervention: 3-month diabetes self-management education (DSME) program alone
Number of subjects: 106
Study: 23100082

Group type: EXPERIMENTAL
Intervention: Ozone treatment via major autohemotherapy (10 sessions)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Betahistine (48 mg/day for 3 months)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 68
Study: 21203694

Group type: EXPERIMENTAL
Intervention: Bungee jumping
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol pretreatment for 3 days
Number of subjects: 20
Study: 18484559

Group type: EXPERIMENTAL
Intervention: Moderate insulin infusion (0.8 microU/kg/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High insulin infusion (1.6 microU/kg/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (blood glucose lowered to 2.5 mmol/l)
Number of subjects: 16
Study: 16174656

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg tid)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 14662282

Group type: EXPERIMENTAL
Intervention: FDG PET-guided therapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 206
Study: 11451177

Group type: EXPERIMENTAL
Intervention: HBV vaccination (preS2/S, GenHevac B, Pasteur‐Mérieux), 20 microg, five intramuscular injections
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HBV vaccination (S vaccine, Recombivax Merck & Co.), five intramuscular injections
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HBV vaccination (any vaccine), five injections
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HBV vaccination (any vaccine)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 118
Study: 9749236

Group type: EXPERIMENTAL
Intervention: Desynchronised mode of extracorporal lithotripsy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Synchronised mode of extracorporal lithotripsy
Number of subjects: 25
Study: 7799770

Group type: COMPARATOR
Intervention: 20 g.l‐1 glucose solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 40 g.l‐1 glucose solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 60 g.l‐1 glucose solution
Number of subjects: 6
Study: 3288818

Group type: EXPERIMENTAL
Intervention: self-care communication-based health education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: control group
Number of subjects: 0
Study: 30737338

Group type: EXPERIMENTAL
Intervention: STN-DBS
Number of subjects: 251

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 251
Study: 29031889

Group type: EXPERIMENTAL
Intervention: Pressure garment therapy (PGT)
Number of subjects: 40
Study: 27680407

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily until disease progression or unacceptable toxicity
Number of subjects: 92
Study: 25073663

Group type: EXPERIMENTAL
Intervention: peginterferon-β1a 125 µg via single-use autoinjector
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: single-use autoinjector
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo via manual pre-filled syringe (PFS)
Number of subjects: 39
Study: 21983985

Group type: EXPERIMENTAL
Intervention: Dialysate with low K (2 mmol/L), low Ca (1.25 mmol/L), high bicarbonate (34 mmol)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dialysate with high K (3 mmol/L), high Ca (1.75 mmol/L), bicarbonate (30 mmol)
Number of subjects: 22
Study: 19923061

Group type: EXPERIMENTAL
Intervention: Premarin (0.3 mg/day and 0.6 mg/day alternately, n=29)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Kuntai capsule (4 g/day, n=28)
Number of subjects: 57
Study: 18086001

Group type: EXPERIMENTAL
Intervention: RLIP76 polymorphisms in the whole cohort
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: RLIP76 polymorphisms in a subgroup of patients on carbamazepine
Number of subjects: 503
Study: 15345733

Group type: EXPERIMENTAL
Intervention: 0.25 mg/day micronized 17beta-estradiol (E2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg/day micronized 17beta-estradiol (E2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg/day micronized 17beta-estradiol (E2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11665348

Group type: EXPERIMENTAL
Intervention: Regular toothpaste
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Triclosan-containing toothpaste
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no toothpaste)
Number of subjects: 20
Study: 10209728

Group type: EXPERIMENTAL
Intervention: Oral brovincamine (20 mg three times daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 52
Study: 8527278

Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 8
Study: 2240348

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study: 722768

Group type: EXPERIMENTAL
Intervention: Ratings administered immediately before or after the final examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mail survey after receiving grades
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ratings from students present on the last two days of class
Number of subjects: 0
Study: 31177364

Group type: EXPERIMENTAL
Intervention: Conventional technique (fixed anastomosis 200 cm from the ligament of Treitz)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Distal technique (anastomosis 400 cm from the ileocecal valve)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 60
Study: 28667208

Group type: EXPERIMENTAL
Intervention: Referral letters with checklist assistance
Number of subjects: 25

Group type: COMPARATOR
Intervention: Referral letters without checklist assistance
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Checklists
Number of subjects: 25
Study: 26468479

Group type: EXPERIMENTAL
Intervention: Desmopressin plus oxybutynin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Desmopressin plus tolterodine
Number of subjects: 59
Study: 23536395

Group type: EXPERIMENTAL
Intervention: NODPAM intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 21310559

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Handgrip test
Number of subjects: 150
Study: 19873916

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Baihui (GV 20) and Taiyang (EXHN 5), once daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Modified Electric Convulsive Therapy (MECT, treatment once every 2 or 3 days for 14 to 21 days)
Number of subjects: 80
Study: 18214053

Group type: EXPERIMENTAL
Intervention: Ondansetron conventional tablet (OT) 8 mg twice daily for 3 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ondansetron orally disintegrating tablet (ODT) 8 mg twice daily for 3 days
Number of subjects: 134
Study: 15126539

Group type: EXPERIMENTAL
Intervention: Dutasteride 5.0 mg
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 399

Group type: COMPARATOR
Intervention: Finasteride 5 mg
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 11414666

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (6 g daily for three days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 0
Study: 9598844

Group type: EXPERIMENTAL
Intervention: Black tea (6 cups per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Green tea (6 cups per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water (control group, 6 cups per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Green tea polyphenols (3.6 grams per day)
Number of subjects: 16
Study: 9215320

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA daily for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 40
Study: 1917031

Group type: EXPERIMENTAL
Intervention: Cefaclor (250 mg t.i.d. for seven days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Amoxycillin (250 mg t.i.d. for seven days)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 84

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 84
Study: 7042501

Group type: EXPERIMENTAL
Intervention: Cefamandole prophylactic therapy
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 31020480

Group type: EXPERIMENTAL
Intervention: IRI + Pmab
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (irinotecan, fluoropyrimidines, and panitumumab)
Number of subjects: 48
Study: 27912111

Group type: EXPERIMENTAL
Intervention: Ictal-MEG source localization (SL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no ictal-MEG data)
Number of subjects: 32
Study: 26660491

Group type: EXPERIMENTAL
Intervention: 1.5% 3-butenyl 5-aminolevulinate gel (ALA-bu)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vehicle application (control)
Number of subjects: 46
Study: 25539512

Group type: EXPERIMENTAL
Intervention: Riluzole (100-200mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Riluzole responders
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FHP riluzole responders
Number of subjects: 52
Study: 22425373

Group type: EXPERIMENTAL
Intervention: Breast Cancer Patient Pathway program (Intervention)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (Control)
Number of subjects: 98
Study: 20118007

Group type: EXPERIMENTAL
Intervention: Bile reinfusion group (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exclusive external drainage group (control group, n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40